Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.70, No.1, p. 1–14, 2023 |
||
Title: PARP in colorectal cancer: Molecular mechanisms, immunity, clinical trials, and drug combinations | ||
Author: Fa-Hong Wu, Hang-Zhi Wei, Hong-Yang Deng, Guo-Hui Xiao, You-Cheng Zhang | ||
Abstract: The changes in cell homeostasis in the tumor microenvironment may affect the development of colorectal cancer (CRC). Genomic instability is an important factor. Persistent genomic instability leads to epigenetic changes, and mutations are a major factor in the progression of CRC. Based on these mechanisms, it is reasonable to link poly (ADP-ribose) polymerase (PARP) with the treatment of colorectal cancer. PARP is mainly involved in DNA repair, which has an essential role in the DNA damage response and prevention of DNA damage, and maintains oxidation and superoxide redox homeostasis in the intracellular environment of the tumor. This article reviews the latest research progress on PARP and PARP inhibitors (PARPi) in CRC. It mainly includes molecular mechanisms, immunity, clinical trials, and combination strategies of CRC. The research of PARPi in CRC has broad prospects, and the combinations with other drugs are the main research direction in the future. |
||
Keywords: PARP; colorectal cancer; DNA damage; immunity; clinical trial | ||
Published online: 02-Sep-2022 | ||
Year: 2023, Volume: 70, Issue: 1 | Page From: 1, Page To: 14 | |
doi:10.4149/neo_2022_220724N745 |
||
|
download file |
|